A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-na < ve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus
- Authors
- Lim, Young-Suk; Ahn, Sang Hoon; Lee, Kwan Sik; Paik, Seung Woon; Lee, Youn-Jae; Jeong, Sook-Hyang; Kim, Ju-Hyun; Yoon, Seung Kew; Yim, Hyung Joon; Tak, Won Young; Han, Sang-Young; Yang, Jenny C.; Mo, Hongmei; Garrison, Kimberly L.; Gao, Bing; Knox, Steven J.; Pang, Phillip S.; Kim, Yoon Jun; Byun, Kwan-Soo; Kim, Young Seok; Heo, Jeong; Han, Kwang-Hyub
- Issue Date
- Nov-2016
- Publisher
- SPRINGER
- Keywords
- Genotype 1; Hepatitis C virus (HCV); Korea; Ledipasvir; Sofosbuvir
- Citation
- HEPATOLOGY INTERNATIONAL, v.10, no.6, pp.947 - 955
- Journal Title
- HEPATOLOGY INTERNATIONAL
- Volume
- 10
- Number
- 6
- Start Page
- 947
- End Page
- 955
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/7715
- DOI
- 10.1007/s12072-016-9726-5
- ISSN
- 1936-0533
- Abstract
- The standard-of-care regimen for chronic hepatitis C virus (HCV) infection in Korea, pegylated-interferon-alpha plus ribavirin, is poorly tolerated. Ledipasvir/sofosbuvir is a two-drug, fixed-dose combination tablet approved in the USA, European Union, and Japan for chronic genotype 1 HCV infection. This single-arm, phase IIIb study (NCT02021656) investigated the efficacy and safety of ledipasvir/sofosbuvir fixed-dose combination tablet for 12 weeks in treatment-na < ve and treatment-experienced Korean patients chronically infected with genotype 1 HCV with or without compensated cirrhosis. The proportion of patients with sustained virologic response 12 weeks after treatment discontinuation (SVR12) was 99 % (92/93), with rates of 100 % (46/46) and 98 % (46/47) in treatment-na < ve and treatment-experienced patients, respectively. There were no on-treatment failures. One patient relapsed after the end of treatment. The most common treatment-emergent adverse events were headache (8 %, 7/93) and fatigue (6 %, 6/93). There were no grade 3 or 4 adverse events, seven grade 3 laboratory abnormalities, and one premature discontinuation of study treatment (due to nonserious mouth ulceration). None of the three reported serious adverse events were related to treatment. These data suggest that 12 weeks of ledipasvir/sofosbuvir is effective and well tolerated in treatment-na < ve and treatment-experienced Korean patients with chronic genotype 1 HCV infection.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/7715)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.